Despite recent advances in treatment, metastatic breast cancer (mBC) remains one of the leading causes of cancer-related deaths in the United States among women. And the prevalence of mBC has also been increasing. In the United States, almost 170,000 women were estimated to be living with the disease in 2020. Hatem Soliman, MD, from The Center for Women's Oncology at Moffitt Cancer Center, discusses how he manages his patients with metastatic recurrence following first-line therapy. Watch Video ›

The long-term results of the HER2Climb trial, which compared TUKYSA® (tucatinib) to trastuzumab and capecitabine in patients with HER2-positive metastatic breast cancer (mBC) with and without brain metastases, were presented at ASCO this year. The results generated a significant amount of interest among physicians who manage women with HER2-positive mBC. Please join Hatem Soliman, MD, from The Center for Women's Oncology at Moffitt Cancer Center, as he discusses some of the pivotal data from the HER2Climb trial at ASCO this year. Watch Video ›

ASCO 2021 is in the rearview mirror but there were plenty of highlights, especially regarding metastatic breast cancer. Please join Hatem Soliman, MD, from The Center for Women's Oncology at Moffitt Cancer Center, as he discusses some interesting data from key metastatic breast cancer trials from the ASCO meeting. Watch Video ›